Fasching, P. A., Schmatloch, S., Hauke, J., Rey, J., Jackisch, C., Klare, P., . . . Loibl, S. (2025). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatin in patients with HER2-negative breast cancer and HRD: Long-term survival of the GeparOLA study. Clinical cancer research, 31(9), . https://doi.org/10.1158/1078-0432.CCR-24-2806
Chicago-Zitierstil (17. Ausg.)Fasching, Peter Andreas, et al. "Neoadjuvant Paclitaxel/olaparib in Comparison to Paclitaxel/carboplatin in Patients with HER2-negative Breast Cancer and HRD: Long-term Survival of the GeparOLA Study." Clinical Cancer Research 31, no. 9 (2025). https://doi.org/10.1158/1078-0432.CCR-24-2806.
MLA-Zitierstil (9. Ausg.)Fasching, Peter Andreas, et al. "Neoadjuvant Paclitaxel/olaparib in Comparison to Paclitaxel/carboplatin in Patients with HER2-negative Breast Cancer and HRD: Long-term Survival of the GeparOLA Study." Clinical Cancer Research, vol. 31, no. 9, 2025, https://doi.org/10.1158/1078-0432.CCR-24-2806.